Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

J. Schuurhuis, Gerrit; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; K. Hills, Robert; S. Hourigan, Christopher; L. Jorgensen, Jeffrey; Kern, Wolfgang; Lacombe, Francis; Maurillo, Luca; Preudhomme, Claude; A. van der Reijden, Bert; Thiede, Christian; Venditti, Adriano; Vyas, Paresh; L. Wood, Brent; B. Walter, Roland; Döhner, Konstanze; J. Roboz, Gail; J. Ossenkoppele, Gert

doi:10.1182/blood-2017-09-801498

Public

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Shared by NobleBlocks on Mar 22, 2018 • 12:00 AM UTC

Authors:

Gerrit J. Schuurhuis

Michael Heuser

Sylvie Freeman

Abstract

Abstract Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogen...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!